Tofacitinib With Methotrexate in Third‐Line Treatment of Patients With Active Rheumatoid Arthritis: Patient‐Reported Outcomes From a Phase III Trial

By  

ARTHRITIS CARE AND RESEARCH, Vol. 67, Iss. 4, 2015-04 ,pp. : 475-483

John Wiley & Sons Inc

Access to resources Recommend Favorite

Herpes Zoster Reactivation in Patients With Rheumatoid Arthritis: Analysis of Disease Characteristics and Disease‐Modifying Antirheumatic Drugs

By  

ARTHRITIS CARE AND RESEARCH, Vol. 67, Iss. 12, 2015-12 ,pp. : 1671-1678

John Wiley & Sons Inc

Access to resources Recommend Favorite

Medication Persistence of Disease‐Modifying Antirheumatic Drugs and Anti–Tumor Necrosis Factor Agents in a Cohort of Patients With Rheumatoid Arthritis in Brazil

By  

ARTHRITIS CARE AND RESEARCH, Vol. 68, Iss. 10, 2016-10 ,pp. : 1489-1496

John Wiley & Sons Inc

Access to resources Recommend Favorite

The role of methotrexate and low‐dose prednisolone on adiponectine levels and insulin resistance in patients with rheumatoid arthritis naïve to disease‐modifying antirheumatic drugs

By  

INTERNATIONAL JOURNAL OF RHEUMATIC DISEASES (ELECTRONIC), Vol. 19, Iss. 7, 2016-07 ,pp. : 665-671

John Wiley & Sons Inc

Access to resources Recommend Favorite

Editorial: Inflammation, Disease‐Modifying Antirheumatic Drugs, Lipids, and Cardiovascular Risk in Rheumatoid Arthritis

By  

ARTHRITIS & RHEUMATOLOGY, Vol. 67, Iss. 2, 2015-02 ,pp. : 327-329

John Wiley & Sons Inc

Access to resources Recommend Favorite